Firms will comarket each other’s products and services.

AbD Serotec , the research and diagnostics antibody division of MorphoSys , and BBInternational  signed an agreement to comarket each other’s products and services worldwide.


The agreement will give BBI’s customers access to over 13,000 antibodies and immunological reagents and custom monoclonal antibodies developed from the MorphoSys HuCAL library, along with AbD Serotec’s large- and small-scale antibody production and conjugation services.


AbD Serotec will in turn have direct access to BBI’s complementary range of services for the production of gold-labeled reagents, contract research and development, and manufacture of rapid diagnostic tests for point of care markets.

Previous articleStrategies for Removing Viruses from Cell Lines
Next articleOpsona Receives Commitment for $4.5M in Series B Financing